23 03, 2020

Unflattening the Curve: Minimize the Impact to Patients Who Depend on Your Successful Clinical Trial

By |2020-03-24T12:48:34+00:00March 23rd, 2020|Tags: , , , , |

In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital. Without a proactive and comprehensive strategy in place to manage clinical trials over the coming weeks and maybe months, consequences may be severe –especially for those that need the treatment the most.

3 03, 2020

The Evolution of Digital Therapeutics and the Need for Clinical Evidence: Lessons Learned from DTx West 2020

By |2020-03-24T12:58:10+00:00March 3rd, 2020|Tags: , , , , , , |

With digital therapeutics experiencing an evolution, Biorasi was on hand at DTx West 2020 to highlight the importance of evidence as a differentiator in clinical trials. Read more about our event experience >>

20 02, 2020

Biorasi Welcomes Chris O’Brien as Chief Executive Officer

By |2020-04-03T09:22:50+00:00February 20th, 2020|Tags: |

Biorasi, LLC and its Board of Directors are proud to announce the appointment of Chris O’Brien to the position of Chief Executive Officer (CEO). O’Brien will assume day-to-day leadership of Company operations, working closely with the Biorasi leadership team to deliver cutting-edge solutions for clinical research project management.

4 02, 2020

WSCS 2020 Wrap Up: Biorasi joins the global dialogue for regenerative medicine

By |2020-02-04T18:05:29+00:00February 4th, 2020|Tags: , , , , , |

When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the regenerative medicine industry, Biorasi had more than one reason to be excited about the event. Read the full article for highlights >>

30 10, 2019

NORD Breakthrough Summit: 3 Key Takeaways

By |2019-11-18T16:39:51+00:00October 30th, 2019|Tags: , , , |

A team from Biorasi joined more than 900 leaders from the FDA, NIH and the pharma and bio-pharma industries for the National Organization for Rare Disorders (NORD) & Orphan Products Breakthrough Summit. Throughout two packed days of keynotes, breakout sessions and panel discussions, we gained valuable insight into the most urgent rare disease topics. Read about the a few takeaways from the event in this article.

20 09, 2019

Strategies for Successful Digital Therapeutics Clinical Trials

By |2020-01-31T16:22:10+00:00September 20th, 2019|Tags: , , |

As digital therapeutics are integrated into every aspect of the healthcare landscape, patients, payers, and providers are seeing an increasingly complex set of software-driven therapy options reaching the market. This rapidly expanding field has enormous potential but faces challenges at every stage, from design to patient perception. Focusing on the clinical trial stage, how does the trial of a digital therapeutic compare to that of a pharmaceutical? What are the specific challenges of running a digital therapeutics clinical trial, and how can sponsors adapt their approach for the highest chance of success?

4 09, 2019

Acute Kidney Injury (AKI): Management and Outcome

By |2020-02-03T11:46:33+00:00September 4th, 2019|Tags: , , , |

In my previous article, I explained the types, causes and symptoms of Acute Kidney Injury (AKI). Here, I’ll share how physicians treat and manage AKI, as well as what to expect. CRRT or intermittent hemodialysis? To treat AKI, nephrologists primarily use renal replacement therapy (RRT), which includes intermittent hemodialysis, peritoneal hemodialysis, various forms of CRRT, and “hybrid” therapies such as prolonged intermittent renal replacement therapy (PIRRT) or sustained low-efficiency hemodialysis (SLED). A few clinical trials are taking a look at CRRT and intermittent hemodialysis under different conditions.

27 08, 2019

Acute Kidney Injury (AKI): Why aggressive treatment early is a must

By |2020-02-07T10:36:05+00:00August 27th, 2019|Tags: , |

What is AKI? AKI is a sudden, reversible decline in the kidney’s glomerular filtration rate (GFR); in other words, its ability to filter metabolic waste. This kidney damage causes an elevation of serum urea and creatinine, which affects the body's ability to function properly. Most AKI cases are reversible. However, it's important to treat AKI as early as possible to avoid its progression to chronic kidney disease or kidney failure.

Download our Precision Medicine Checklist

Complete the form below to receive a link to download this checklist
close-link

Schedule a call with one of our experts today

Let us know how we can help. Our team would like to connect with you!
close-link

Start your FREE Trial Rescue Assessment!

Complete the form below and we will provide our free trial rescue assessment.
close-link

Download our Patient-Centric Trials White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Data Science White Paper

Complete the form below to receive a link to download this white paper
close-link

Schedule a TALOS™ Control Center Demo

Complete the form below to schedule a demo with our program development team
close-link

Download our Rare Disease Checklist

Complete the form below to receive a link to download this checklist
close-link

Download our Dermatology White Paper

Complete the form below to receive a link to download this white paper
close-link

Get Access to "Making Most of Trial Data" Webinar

Complete the form below to receive a link to access this webinar
close-link

Download our Precision Oncology White Paper

Complete the form below to receive a link to download this whitepaper
close-link

Download Rare Disease Program Development White Paper

Complete the form below to receive a link to download this whitepaper
close-link

Get access to "Strategies for Successful Digital Therapeutics Clinical Trials" Webinar

Complete the form below to receive a link to access this on-demand webinar
close-link

Schedule a call with one of our experts today

Let us know how we can help. Our team would like to connect with you!
close-link

Schedule a call with one of our experts today

Let us know how we can help. Our team would like to connect with you!
close-link

Download our Trial Rescue White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Advance Analytics Monitoring White Paper

Complete the form below to receive a link to download this white paper
close-link

Download our Nephrology Clinical Trials White Paper

Complete the form below to receive a link to download this resource
close-link

Download our Regulatory Clinical Trial White Paper

Complete the form below to receive a link to download this white paper
close-link

Download ANDA Program Optimization WP

Complete the form below to receive a link to download this white paper
close-link

Get Access to "Solving at Risk Trials" Webinar

Complete the form below to receive a link to access this on-demand webinar
close-link
Biorasi uses cookies for analytics to improve your experience on this website. By continuing to browse this site, you agree to this use. Please review our Privacy Policy for more information. Ok